metoprolol has been researched along with Metabolic Syndrome in 4 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the effect of nebivolol (5 mg/d) and the β(1)-selective antagonist metoprolol (100 mg/d) on glucose homeostasis and markers of fibrinolysis in 46 subjects with metabolic syndrome." | 9.16 | Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. ( Ayers, K; Brown, NJ; Byrne, LM; DeMatteo, A, 2012) |
| "The aim of this work was to study effects of metoprolol on structural and functional characteristics of left ventricle (LV), cerebral circulation (CC), microcirculation (MC), lipid spectrum, rheologic and viscous properties of blood in patients with grade II-III hypertensive disease (HD) and metabolic syndrome." | 7.76 | [Hypertensive disease and metabolic syndrome: application of metoprolol]. ( Koren'kov, VV; Markova, EV; Markova, LI; Radzevich, AE; Samoĭlenko, TN; Sokolova, NV, 2010) |
| " We compared the effect of nebivolol (5 mg/d) and the β(1)-selective antagonist metoprolol (100 mg/d) on glucose homeostasis and markers of fibrinolysis in 46 subjects with metabolic syndrome." | 5.16 | Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. ( Ayers, K; Brown, NJ; Byrne, LM; DeMatteo, A, 2012) |
| "The aim of this work was to study effects of metoprolol on structural and functional characteristics of left ventricle (LV), cerebral circulation (CC), microcirculation (MC), lipid spectrum, rheologic and viscous properties of blood in patients with grade II-III hypertensive disease (HD) and metabolic syndrome." | 3.76 | [Hypertensive disease and metabolic syndrome: application of metoprolol]. ( Koren'kov, VV; Markova, EV; Markova, LI; Radzevich, AE; Samoĭlenko, TN; Sokolova, NV, 2010) |
| "Insulin resistance was measured by homeostasis assessment index (HOMA)." | 2.73 | Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. ( Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Markova, LI | 1 |
| Radzevich, AE | 1 |
| Koren'kov, VV | 1 |
| Sokolova, NV | 1 |
| Markova, EV | 1 |
| Samoĭlenko, TN | 1 |
| Fang, Y | 1 |
| Nicol, L | 1 |
| Harouki, N | 1 |
| Monteil, C | 1 |
| Wecker, D | 1 |
| Debunne, M | 1 |
| Bauer, F | 1 |
| Lallemand, F | 1 |
| Richard, V | 1 |
| Thuillez, C | 1 |
| Mulder, P | 1 |
| Ayers, K | 1 |
| Byrne, LM | 1 |
| DeMatteo, A | 1 |
| Brown, NJ | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Caglar, K | 1 |
| Celik, T | 1 |
| Yenicesu, M | 1 |
| Eyileten, T | 1 |
| Acikel, C | 1 |
| Oguz, Y | 1 |
| Yavuz, I | 1 |
| Vural, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome[NCT00775671] | Phase 4 | 46 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography[NCT03990480] | Phase 4 | 230 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentration of plasminogen activator inhibitor 1 (PAI-1)antigen. (NCT00775671)
Timeframe: After 12 weeks of study drug
| Intervention | ng/mL (Mean) |
|---|---|
| Nebivolol | 10.5 |
| Metoprolol | 12.3 |
The change in insulin sensitivity index, from baseline to after 12 weeks of treatment. Calculated from the intravenous glucose tolerance test at baseline and at 12 weeks. (NCT00775671)
Timeframe: 3 hours
| Intervention | 10-4xmin-1 per mU/L (Mean) |
|---|---|
| Nebivolol | 0.04 |
| Metoprolol | -1.5 |
2 trials available for metoprolol and Metabolic Syndrome
| Article | Year |
|---|---|
Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.
Topics: Adrenergic beta-Antagonists; Adult; Benzopyrans; Blood Glucose; Blood Pressure; Double-Blind Method; | 2012 |
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2007 |
2 other studies available for metoprolol and Metabolic Syndrome
| Article | Year |
|---|---|
[Hypertensive disease and metabolic syndrome: application of metoprolol].
Topics: Adrenergic beta-1 Receptor Antagonists; Cerebrovascular Circulation; Dose-Response Relationship, Dru | 2010 |
Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Benzopyrans; Disease Models, Animal; Endothelium, V | 2011 |